An interventional study of Heartfelt Device installed and Standard care in Heart Failure and Chronic Heart Failure, sponsored by Heartfelt Technologies. Recruiting at 4 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Heartfelt Technologies · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.
Among the 2,159 studies in Heart Failure with a site in United States, this one is the 108th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 108 that started in 2025, is one of 887 with no phase, reaches primary completion later than 343 of the 438 other live ones, and was the 1,872nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,159 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 313 · Phase 3 177 · Phase 4 139
First in 1983; this study’s year is marked. 108 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 1,602 interventional studies, 150 across the 552 observational. Of the 1,510 that completed or were terminated, 630 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
747 of 2,159 have an industry lead sponsor. The 10 most frequent:
Heartfelt Technologies is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Heartfelt Technologies has 8 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
138 of the studies in Heart Failure with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02901184Phase 3Uppsala UniversitySpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | 2026-12 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 138 to your calendar (.ics) → With an account.
Among the 2,159 studies in Heart Failure with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pragmatic randomized crossover trial looks at the effect(s) of using a remote patient monitoring device (Heartfelt device) with health alerts to monitor the development of peripheral edema in patients with heart failure (HF). The hypothesis is that this passive measurement method will lead to better data availability, which in turn will improve patient care and reduce hospitalizations for the management of worsening HF (HF hospitalizations, HFHs) in nonadherent participants with chronic HF. The study objectives are:
Secondary objectives:
Participants will need to:
Participants will be recruited through Remote Patient Monitoring Providers (RPMPs) based in the US, using crossover randomization between standard care and Heartfelt device usage with health alerts sent to RPMPs. The RPMPs will follow a protocolized intervention when responding to raised alerts.
The study design is a crossover randomization between:
At consent, patients get randomized to an install date over a period from 21 to 60 days following consent, subject to scheduling this at least 14 days after the most recent recorded hospital discharge at the time of consent, or the discharge from their current hospitalization if hospitalized at the time of consent.
Total study length is 366 days (days 0 to 365). There are two 21-day "washout" periods to prevent carryover between study arms. The first washout period extends from day 0-20 inclusive, and the second from day 183-203 inclusive
At the completion of both crossover arms, patients will be offered the opportunity to keep the device for as long as the study remains active (potentially up to an additional 4 years, for those patients recruited early in the study). During this long-term follow-up, the device will be placed in "Intervention" mode, with randomized 100-day periods where the device is switched into "Standard care" mode (control).
The criteria were revised on the registry on Nov 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of heart failure decompensation or elevated risk of future hospitalization, defined by one or more of the following:
Evidence of non-adherence defined by one or more of the following:
Participants with ≥180 days of historical monitoring/device data available
Participants without ≥180 days of historical monitoring/device data available: Evidence of non-adherence may be demonstrated by low data capture over shorter windows, defined as any of the following :
Documented non-adherence in the medical record within the last 3 years:
EXCLUSION CRITERIA
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device is installed and data is captured but volume measurements and health alerts are not transmitted to the RPMP.
Device: Heartfelt Device installed · Other: Standard care · Other: Questionnaires
Device is installed and data is captured, and volume measurements and health alerts are transmitted to the RPMP for review and potential follow-up (per a pre-specified alert protocol).
Device: Heartfelt Device installed · Other: Standard care · Device: Heartfelt-guided care · Other: Questionnaires
Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
Also known as: Remote patient monitoring device
RPMPs in regular contact with patients and collecting health monitoring data as per their standard operating procedures.
Also known as: Daily weighing, Breathlessness, Dizziness, Tiredness
Volume measurements and health alerts transmitted to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.
Also known as: Daily weighing, Remote patient monitoring
Patients were presented with one or more optional questionnaires (some validated, some bespoke)
Also known as: KCCQ, 5Q-5D, PAM Questionnaire, Bespoke Questionnaire
Heart Failure Events (HFEs, a composite of HFH or Worsening HF event without hospitalization (as defined in [1-Abraham])
Used to demonstrate whether the device effectively reduces HFHs and urgent HF visits.
Time frame: 12 months, plus up to 48 months long term follow-up
Doubling in serum creatinine (sCr) from baseline with at least 2.0mg/dL
Used to ensure that increased diuretic treatment following alerts from the device does not lead to significant increase in AKI
Time frame: 12 months, plus up to 48 months long term follow-up
Difference in data availability (device generated or contemporaneous self-report)
Used to measure the data availability from the Heartfelt device. One of the key findings from feasibility trials and pilot studies in the UK have demonstrated an increased data availability. Does this study in the US confirm the previous finding?
Time frame: 12 months, plus up to 48 months long term follow-up
The date and length (in hours) of hospital admission and re-admissions
Used to review the lead time of health alerts, or the lack of health alerts generated prior to hospital admissions.
Time frame: 12 months, plus up to 48 months long term follow-up
Cause of hospitalizations (HF or non-HF)
Used to review the lead time of health alerts, or the lack of health alerts generated prior to hospital admissions.
Time frame: 12 months, plus up to 48 months long term follow-up
Date of increase in HF medications when the patient is home or in the community (not the detailed changes whilst on the ward)
This may include oral diuretic, IV diuretics and subcutaneous furosemide injections. Used to allow the determination if an outpatient appointment is HF related or not.
Time frame: 12 months, plus up to 48 months long term follow-up
Death and cause of death from the clinical record (HF or non-HF as defined in [1-Abraham])
Used to establish if using the device changes HF- or non-HF mortality.
Time frame: 12 months, plus up to 48 months long term follow-up
Loss of independence (patient unable to live at home; for example, relocation to a care facility for an indefinite duration)
Used to establish if there has been an effect on the ability of the patient to live independently in their home.
Time frame: 12 months, plus up to 48 months long term follow-up
Route of admission for hospitalization events (ICU, CCU, or ward admission),and discharge (home, skilled nursing facility and long term care facility).
Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission.
Time frame: 12 months, plus up to 48 months long term follow-up
Scheduling of care events (scheduled or unscheduled)
Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission.
Time frame: 12 months, plus up to 48 months long term follow-up
The setting of care events (inpatient or outpatient)
Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission.
Time frame: 12 months, plus up to 48 months long term follow-up
Date and time of health alerts generated by the Heartfelt device
Used to establish the response time to health alerts.
Time frame: 12 months, plus up to 48 months long term follow-up
Date, time and method of contact made following reception of a health alert generated by the Heartfelt device
Used to establish the response time to health alerts.
Time frame: 12 months, plus up to 48 months long term follow-up
Date and reason for study withdrawal
Used alongside the analysis of other right-censoring endpoints.
Time frame: 12 months, plus up to 48 months long term follow-up
NT Pro-BNP or BNP, with date if available in patient records
Used to correlate NT Pro-BNP health alert status.
Time frame: 12 months, plus up to 48 months long term follow-up
Date and time of health alerts from other monitoring devices
Used to correlate health alerts from other medical devices and the Heartfelt device.
Time frame: 12 months, plus up to 48 months long term follow-up
Symptoms diary (if available)
Used to establish patient usage of symptom diaries.
Time frame: 12 months, plus up to 48 months long term follow-up
Questionnaire responses (if available)
Used to establish patient acceptability of the device.
Time frame: 12 months, plus up to 48 months long term follow-up
Dates, types and length of stays in rehab facilities/nursing home/care homes
Recorded in hours if \<48h and in days if \>48h. Proxy used to identify trends in worsening of patient's health/independence/quality of life following participation in various arms of the study.
Time frame: 12 months, plus up to 48 months long term follow-up
Dates and times of caregivers' shifts if home healthcare used
Proxy used to identify trends in worsening of patient's health/independence/quality of life following participation in various arms of the study.
Time frame: 12 months, plus up to 48 months long term follow-up
HFHs in the 12 months prior to installation (as defined in [1-Abraham])
Used to compare HF Hospitalization date before the study as a baseline period and during the study.
Time frame: Retrospectively, over the 12 months prior to device installation
UHFV and other urgent healthcare usage in the 12 months prior to installation
Used to compare Heart Failure Visit numbers before the study as a baseline period and during the study.
Time frame: Retrospectively, over the 12 months prior to device installation
Date and cause of Death
Used to supplement data on HF-related death that is collected as a primary endpoint from clinical records of participants, as well as allowing the comparison to non-participants.
Time frame: 12 months
Ethnicity
Used to analyze the other endpoints based on this subgroup.
Time frame: At enrollment
NYHA class
Used to analyze the other endpoints based on this subgroup.
Time frame: At enrollment
Ejection fraction
Used to analyze the other endpoints based on this subgroup.
Time frame: At enrollment
Comorbidities
Used to analyze the other endpoints based on this subgroup.
Time frame: At enrollment
Date, prescription fulfillment and any modifications to dosage of HF medications (if available)
Used to get an indication of medication adherence.
Time frame: 12 months, plus up to 48 months long term follow-up
Optimal medical therapy score (if available)
Used to get an indication of medication adherence.
Time frame: 12 months, plus up to 48 months long term follow-up
Presence of edema reported by clinicians during the clinical encounter (including grading of edema if available)
Used to validate the device's determination of edema status.
Time frame: 12 months, plus up to 48 months long term follow-up
Data availability (device generated or contemporaneous self-report) in the 6 months prior to screening.
Used to analyze the other endpoints based on this subgroup.
Time frame: Retrospectively, over the 6 months prior to screening
Device-related complications
Used to ensure that any device-related complications that occur after the main 12 months of the study are captured.
Time frame: 12 months, plus up to 48 months long term follow-up
Date, time, reason and means of contact made with patients by RPMPs not due to Heartfelt health alerts (e.g. phone triage/counseling, repeat labs, etc)
Used to determine if any significant changes in outcomes might be due to increases in patient contacts overall.
Time frame: 12 months, plus up to 48 months long term follow-up
Tobacco consumption
Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup.
Time frame: 12 months, plus up to 48 months long term follow-up
Alcohol consumption
Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup.
Time frame: 12 months, plus up to 48 months long term follow-up
Cannabis consumption
Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup.
Time frame: 12 months, plus up to 48 months long term follow-up
Other recreational drug(s) consumption
Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup.
Time frame: 12 months, plus up to 48 months long term follow-up
Cause of hospitalizations (ICD-10-CM codes)
Used to determine if a correlation could be identified between treatment effect and type of hospital stays; as well as sensitivity and specificity of the alert analysis.
Time frame: 12 months, plus up to 48 months long term follow-up
Not enrolling at this site.
Plan to share: Yes — Data collected for this study will be analyzed and stored by the Sponsor. After the study is completed, the de-identified, archived data will be transmitted to and stored by the Sponsor, for use by other researchers including those outside of the study. Permission to transmit data to the Sponsor will be included in the informed consent. To further reduce the risk of patient identification, we will not associate patients with a named RPMP, we will instead use a site ID for each RPMP. During the conduct of the study, an individual participant can choose to withdraw consent to have their de-identified data stored for future research. However, withdrawal of consent with regard to data storage may not be possible after the study is completed. When the study is completed, access to study de-identified data will be provided through the Sponsor.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 6 months after publication
Access criteria: Contact the Sponsor
Data sharing details ↗ · www.hftech.org
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 38 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Primary completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2028, last on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heartfelt Technologies